Total Research Group LLC

1. Boehringer Ingelheim Pharma GmbH & Co.KG $543,611 24 payments
2. Boehringer Ingelheim Pharmaceuticals, Inc. $527,816 28 payments
3. Boehringer Ingelheim International GmbH $489,388 50 payments
4. Akebia Therapeutics Inc $220,384 136 payments
5. Vertex Pharmaceuticals Incorporated $88,336 3 payments
6. Retrophin, Inc. $6,856 8 payments

1. Empa-Kidney $535,450 43 payments
2. A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease $397,454 15 payments
3. Phase II dose finding PoCC in CKD $383,730 5 payments
4. Akb-6548-Ci-0014 $120,663 94 payments
5. PoCP study in FSGS $94,588 14 payments
6. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $88,336 3 payments
7. Empa Kidney $87,736 2 payments
8. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $80,166 24 payments
9. Phase II dose finding/PoCC in CKD $27,811 1 payment
10. A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD $25,046 21 payments

1. Other $6,856 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.